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CS1-01 Impact of Immunosuppression on Viral Hepatitis B
and C
W. Ray Kim*. Mayo Clinic College of Medicine, Rochester, MN,
USA
Competent immune function is an important determinant of the
natural history of viral hepatitis as well as treatment response.
Hepatitis B virus (HBV) is, in general, thought not to be cyto-
pathic and the hepatic injury in patients with HBV infection is
predominantly immune-related. However, it is well established
that suppression of humoral and/or cellular immune function is
detrimental in patients with chronic HBV infection. Although the
pathogenesis of liver inﬂammation from hepatitis C virus (CV) in-
fection is incompletely understood, abundant T cells aggregated
in lymphoid inﬁltrates in portal areas are involved in the cytolysis
of infected hepatocytes and ﬁbrogenesis.
Common clinical circumstances in which immunosuppression af-
fects viral hepatitis B and C include (1) chemotherapy for
malignancies, (2) solid organ and bone marrow transplantation,
and (3) human immunodeﬁciency virus (HIV) infection.
Reactivation of HBV in the setting of chemotherapy is best
described in patients with lymphoma. Approximately 50% of
HBsAg-positive patients develop a ﬂare of hepatitis during or
shortly after chemotherapy. In a number of studies, the fatality
rate of HBV reactivation is reported to be higher than 10%. The
frequency and severity of HBV reactivation may be inﬂuenced
by the level and duration of immunosuppression as well as the
host HBV factors, such as HBeAg status or serum HBV DNA lev-
els. Because of these signiﬁcant risks of reactivation, antiviral
therapy is usually recommended in patients with HBV undergoing
chemotherapy for malignancies. In a meta-analysis that investi-
gated the role of lamivudine prophylaxis, patients who received
lamivudine was at a much lower risk of developing HBV-related
hepatic failure and dying from HBV-related causes. The impact of
cancer chemotherapy on HCV is much less dramatic than on HBV.
For example, chemotherapy for breast cancer was found to be
safe in women with HCV infection. Although HCV RNA level may
increase in patients receiving rituximab therapy, adverse events
related to HCV are much less frequent compared to HBV and no
formal recommendation is made for screening or treatment for
HCV prior to chemotherapy.
Liver transplantation has been a model with which to study the
impact of immunosuppression in patients with viral hepatitis. In
the absence of prophylaxis against HBV, reinfection of the graft
is almost universal after liver transplantation in patients who
are HBsAg-positive. It is now well established that reinfection
of the graft can be effectively prevented by hepatitis B immune
globulin and oral antiviral agents. Unfortunately, prevention of
graft reinfection is not possible with HCV and the vast majority
of liver transplant recipients do develop recurrent HCV infec-
tion. Subsequently, progression of disease progression is more
rapid in these patients receiving immunosuppression than in im-
mune competent patients. Response to anti-HCV therapy is also
reduced in liver transplant recipients.
For other solid organ transplants, HBsAg-positive recipients face
a high rate of reactivation of HBV. While some believe that
HBV reactivation in these patients is not as detrimental as
in liver transplant recipients, antiviral prophylaxis is usually
recommended. Since interferon-based anti-HCV therapy is con-
traindicated in patients with renal or heart transplantation,
careful selection of HCV-positive candidates is necessary includ-
ing consideration of combined liver transplantation in patients
with advanced liver disease.
HIV infection signiﬁcantly affects the natural history of HBV and
HCV. HIV coinfection increases the risk of cirrhosis in patients
with HBV, although these patients tend to have lower ALT levels.
More importantly, HIV-HBV co-infection increases liver-related
mortality 17 times compared to HBV mono-infection. Similarly,
the risk of cirrhosis is two fold increased in patients with HIV-HCV
co-infection. Since the introduction of highly active antiretro-
viral therapy, HCV-related liver disease has become a major
cause of morbidity and mortality in HIV infected patients. In
the US, screening for HIV is recommended for all patients with
HCV infection and HBV patients with risk factors. Individualized
treatment decisions are necessary for optimal outcome in these
patients.
CS1-02 The Role of HBV Viral Quasispecies in HBeAg
Seroconversion
Seng-Gee Lim*. National University Health System, Singapore
Hepatitis B virus (HBV) viral quasispecies may have impor-
tant roles in pathogenicity similar to quasispecies in hepati-
tis C and HIV. We had previously characterized the evolu-
tion of HBV quasispecies in HBeAg seroconverters compared
to non-seroconverters. We examined cohorts of well deﬁned
clinical phenotypes of chronic hepatitis B, HBeAg serocon-
verters and non-seroconverters with and without interferon
therapy who were followed over 60 months. Serum was used
for nested PCR, cloning and sequencing of the precore/core
gene (20 clones/sample). Only patients with genotype B were
used. Sequences were aligned using ClustalX, then sUPGMA
phylogenetic trees were constructed using Pebble 1.0 fol-
lowing which maximum likelihood estimates of pairwise dis-
tances under a GTR+I+G model was assessed. Viral diversity
and substitution rates were then estimated. Results of anal-
ysis of 3386 sequences showed that HBeAg seroconverters
had 2.4-fold higher pre-seroconversion viral sequence diver-
sity (p=0.0183), and 10-fold higher substitution rate (p<0.0001)
than non-seroconverters, who had persistently low viral diver-
sity (3.6×10-3 substitutions/site) and substitution rate (2.2×10-5
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substitutions/site/month). Following seroconversion, there was
a striking increase in viral diversity. Most seroconverters had
viral variants that showed evidence of positive selection, which
was seen mainly postseroconversion. Conclusions: The high viral
diversity before a reduction in HBV DNA and before HBeAg sero-
conversion, could either be related to occurrence of stochastic
mutations that lead to a break in immune tolerance, or increased
immune reactivity that drives escape mutations. In a follow-up
study, we examined the long term evolution of HBV quasispecies
and whether the increase in viral diversity could be conﬁrmed.
Furthermore, we sought to determine if this increase in viral
diversity could result in creation of new CpG motifs, which could
stimulate Toll Receptor 9. TLR9 is one member of a family of
highly conserved molecular pattern recognition receptors-toll
like receptors, and is stimulated by unmethylated CpG dinu-
cleotides resulting in activation of the innate immune response
and consequently adaptive immune response. In this study, we
analyzed if there were any CpG sites in the HBV genome of
chronic hepatitis B patients and their relationship with HBeAg
seroconversion, using Eight HBeAg seroconverters followed up
6–10 years before seroconversion were included. Serum samples
of 5 to 9 time points before HBeAg seroconversion were used
in the study. Seven non-seroconverters with matching follow up
period and stored serum samples were involved as controls. An
identical methodology was used to evaluate 20 clones per serum
sample and analysed using the same methodology as previously.
HBV CpGs status was analyzed with the sequence alignments.
Results: The HBV quasispecies viral diversity gradually increased
from 1.4×10-3 to 1.2×10-2 within 9 years before HBeAg serocon-
version. Positive selection was detected in 5 of 8 seroconverters
in the study period. New CpG motifs also emerged before HBeAg
seroconversion. The increase of viral diversity was closely corre-
lated with the reduction of HBV DNA, HBeAg levels and increase
in frequency of precore stop codon mutation.
Conclusion: The gradual increase of HBV quasispecies over time
before HBeAg seroconversion could be related to accumulation
of stochastic mutations which result in occurrence of new CpG
motifs that activated the innate immune response and break the
immune tolerance leading to HBeAg seroconversion.
CS1-03 Immunological Effects of Type I Interferons in
Hepatitis B Revisited: How Does Interferon Work
against HBV?
Heiner Wedemeyer*. Klinik für Gastroenterologie, Hepatologie
und Endkrinologie, Medizinische Hochschule Hannover,
Hannover, Germany
Type I interferons have been used for almost 25 years to treat
hepatitis virus infections. While HCV infection can be cured in
50-80% of cases with IFN-based treatment regimens, the goal
of IFN-therapy of HBV infection is to induce an immune control
which is either associated with HBe seroconversion or even loss
of HBsAg. Obvious advantages of IFN therapies of chronic hep-
atitis B are ﬁnite treatment durations, the lack of resistance
development and higher off-treatment sustained response rates
as compared to HBV polymerase inhibitors. However, IFN alfa
may induce various side effects and the direct antiviral potency
is much weaker as compared to the recently approved nucleoside
and nucleotide analogues. The detailed mode of action of IFN
alfa in the treatment of chronic hepatitis B is poorly deﬁned.
Different effect of IFNa have been proposed: (i) IFNa directly
inhibits HBV replication which has been conﬁrmed by in vtro
models of HBV replication. (ii) IFNa may display various effects
on cells of the adaptive immune system including dendritic cells
and T cells. Some but not all studies suggest an impairment of
dendritic cells in chronic hepatitis B and IFNa may may enhance
antigen presentation, cytokine production and maturation of
dendritic cells. If IFNa treatment is associated with a reduction
of the in HBV infection increased frequency of regulatory T
cells (Tregs) has not been studied in detail yet. Impaired CD8+
T cell function is associated with a higher expression of PD-1
expression and blocking PD1-signalling can restore T cell activity.
It is generally believed that T cell function should be increased
by IFNa, however, IFNa has also antiproliferative capacities and
may therefore impair T cell proliferation. (iii) IFNa is believed
to enhance NK cell functions. We gained evidence that IFNa
increases the cytotoxic activity of NK cells via various mecha-
nisms including upregulation of certain molecules such as TRAIL.
(iv) The potential effects of IFNa on humoral immunity against
HBV are poorly deﬁned but several studies have shown already
that B cell priming and BCR crosslinking is improvied by IFNa.
(v) Toll-like receptor-2 expression is reduced in HBeAg-positive
hepatitis B. Preliminary data suggest that IFNa may increase
TLR-2 expression.
Overall, IFNa treatment is associated with a reduced virion
productivity. To what extent this due to direct intracellular
mechanisms or deletion of HBV-infected cells remains to be
determined. Future studies will have to deﬁne in more de-
tail which patients are good candidates of IFNa treatment and
which patients may beneﬁt from combination therapies with HBV
polymerase inhibitors.
CS1-04 Gender and HBV – Interaction between Human
Sex Hormones and HBV Transcription/Replication
Pei-Jer Chen*. National Taiwan University and Hospital, Taipei,
Taiwan
One interesting outcome of chronic hepatitis B virus infection
has been a more common development of end-stage liver dis-
eases in males than females. This gender disparity is more
striking in HBV-related liver cancer, in which male patients usu-
ally outnumber females to 5-7 folds. The hypothesis is proposed
either males more vulnerable to HBV-carcinogenesis or females
more protective against this process, or both. The hypothesis
has been supported by epidemiological investigations in which
higher androgen levels are correlated with more risk of HCC in
male carriers, and use of estrogen supplements reduces HCC
in female carriers. Now we present the results how human sex
hormones axis interacts with HBV. It was found that androgen
receptor could bind directly to HBV genome, via enhancer I, to
augment HBV transcription and replication. Besides, androgen
receptor can cooperate with HBV X protein to enhance down-
stream cancer-promoting pathway. In contrast, there are data
indicating female estrogen receptor able to down regulate HBV
gene transcription, maybe via a remodeling of viral genome. The
addition of estrogen to male HBV transgenic mice could reduce
HBV titers. These results may explain the mechanisms for a male
susceptibility to HBV-related end stage liver diseases and might
point out directions to anti-viral targets.
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CS2-01 Clostridium difﬁcile Infections
Po-Ren Hsueh*. Divisions of Clinical Microbiology and Infectious
Diseases, Departments of Laboratory, Medicine and Internal
Medicine, National Taiwan University Hospital, National Taiwan;
University College of Medicine, Taipei, Taiwan
Currently, Clostridium difﬁcile rivals methicillin-resistant
